Cytokinetics Inc (NASDAQ:CYTK) price on Thursday, April 10, rose 1.42% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $37.85.
A look at the stock’s price movement, the close in the last trading session was $37.32, moving within a range at $35.19 and $38.42. The beta value (5-Year monthly) was 0.939. Turning to its 52-week performance, $75.50 and $32.74 were the 52-week high and 52-week low respectively. Overall, CYTK moved -13.96% over the past month.
Cytokinetics Inc’s market cap currently stands at around $4.51 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-26.
The average forecast suggests up to a 243.91% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 35.71M, representing a 93.30% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that CYTK is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
12 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 11 recommend CYTK as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CYTK’s current price about -8.47% and -13.93% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 40.71, while 7-day volatility ratio is 12.55% and 7.27% in the 30-day chart. Further, Cytokinetics Inc (CYTK) has a beta value of 0.84, and an average true range (ATR) of 3.24. Analysts have given the company’s stock an average 52-week price target of $93.5, forecast between a low of $67 and high of $120. Looking at the price targets, the low is -77.01% off current price level while to achieve the yearly target high, price needs to move -217.04%. Nonetheless, investors will most likely welcome a -147.03% jump to $93.5 which is the analysts’ median price.
If we refocus on Cytokinetics Inc (NASDAQ:CYTK), historical trading data shows that trading volumes averaged 2.87 over the past 10 days and 1.86 million over the past 3 months. The company’s latest data on shares outstanding shows there are 118.21 million shares.
The 2.60% of Cytokinetics Inc’s shares are in the hands of company insiders while institutional holders own 109.82% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 14.22 million on 2025-03-14, giving us a short ratio of 7.82. The data shows that as of 2025-03-14 short interest in Cytokinetics Inc (CYTK) stood at 1829.0001 of shares outstanding, with shares short falling to 15.07 million registered in 2025-02-14. Current price change has pushed the stock -19.54% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CYTK stock continues to rise going into the next quarter.
